Clinical trial · Interventional
Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer
A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is accepted that giving higher doses of chest radiation in as short a time span as possible improves chances of cure. In this study, the investigators propose to give an increased dose of chest radiotherapy for limited stage small cell lung cancer patients using a strategy of giving a slightly higher daily dose of radiotherapy than normal. The investigators hypothesize that our proposed chest radiotherapy dose will improve 2-year overall survival rates in patients with limited stage small cell lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasm | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Small Cell Carcinoma | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Chest Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 2-year overall survival
- timeFrame
- 2011
Secondary outcomes (2)
- measure
- Quality of life
- timeFrame
- 2011
- measure
- Patterns of Failure
- timeFrame
- 2011
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * limited stage small cell lung cancer * adequate pulmonary function test (FEV1 \>1.0 L, DLCO \>50%) * signed study consent * age at least 18 years * Karnofsky performance status as least 70% * eligible to receive standard concurrent small cell cancer chemotherapy Exclusion Criteria: * extensive stage disease * mixed non small cell and small cell histology * inadequate pulmonary function tests * not eligible for concurrent chemotherapy * subtotal or total tumor resection * previous chest/neck radiotherapy * prior or concurrent malignancy except non-melanomatous skin unless disease free for last 5 years * pregnant * prior chemotherapy for another malignancy * patients with myocardial infarction within the preceding 6 months of symptomatic heart disease, including, angina, congestive heart failure, uncontrolled arrhythmias
References
Publications (0)
Data not yet available